<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121420</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-0224</org_study_id>
    <nct_id>NCT00121420</nct_id>
  </id_info>
  <brief_title>Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases</brief_title>
  <official_title>Phase II Trial of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to evaluate if motexafin gadolinium with whole brain
      radiation therapy followed by a stereotactic radiosurgery boost is a safe and effective
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive three weeks of whole brain radiation therapy concurrent with daily
      motexafin gadolinium during weeks 2 and 3, followed by a stereotactic radiosurgery boost
      concurrent with motexafin gadolinium. Patients will be followed for radiologic response,
      neurologic progression, and neurocognitive progression.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of irreversible Grade 3 or any Grade 4 or 5 neurologic radiation toxicities occuring within 3 months following SRS boost</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lesion size and number between screening MRI and SRS treatment -planning MRI</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neuroligic progression or death with evidence of neurologic progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neurocognitive progression</measure>
  </secondary_outcome>
  <enrollment>45</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <condition>Brain Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motexafin gadolinium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Karnofsky performance status (KPS) ≥ 70

          -  Histologically confirmed malignancy with the presence of one to four intraparenchymal
             brain metastases

          -  Each patient must sign a study-specific Informed Consent form

        Exclusion Criteria:

          -  Previous cranial radiation

          -  Complete resection of all known brain metastases

          -  Known leptomeningeal metastases

          -  Known liver metastases

          -  Clinical or radiologic evidence of progression (other than study lesion[s) within 1
             month prior to enrollment

          -  Patients with metastases within 10 mm of the optic apparatus

          -  Patients with metastases in the brainstem, midbrain, pons, or medulla

          -  Planned chemotherapy during WBRT and/or SRS

          -  Uncontrolled hypertension

          -  Women who are pregnant or lactating

        and Laboratory values as follows:

          -  LDH &gt; 1.3 x upper limit of normal (ULN)

          -  ANC &lt; 1500/mm3

          -  Platelets &lt; 50,000/mm3

          -  Creatinine &gt; 2.0 mg/dL

          -  AST or ALT &gt; 3 x ULN

          -  Total bilirubin &gt; 2 x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minesh P Mehta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.braintumor.org</url>
    <description>National Brain Tumor Foundation</description>
  </link>
  <link>
    <url>http://pharmacyclics.com</url>
    <description>Pharmacyclics</description>
  </link>
  <reference>
    <citation>Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz C, Timmerman R, Curran W, Smith J, Phan SC, Miller RA, Renschler MF. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003 Jul 1;21(13):2529-36.</citation>
    <PMID>12829672</PMID>
  </reference>
  <reference>
    <citation>Evens AM. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol. 2004 Nov;16(6):576-80. Review.</citation>
    <PMID>15627019</PMID>
  </reference>
  <reference>
    <citation>Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther. 2005 Jan;4(1):6-13. Epub 2004 Jan 8. Review.</citation>
    <PMID>15684606</PMID>
  </reference>
  <reference>
    <citation>Manon R, Hui S, Chinnaiyan P, Suh J, Chang E, Timmerman R, Phan S, Das R, Mehta M. The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme. Technol Cancer Res Treat. 2004 Jun;3(3):303-7.</citation>
    <PMID>15161323</PMID>
  </reference>
  <reference>
    <citation>Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004 Jan 1;22(1):157-65.</citation>
    <PMID>14701778</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain Neoplasms/secondary</keyword>
  <keyword>Brain neoplasms/radiotherapy</keyword>
  <keyword>Brain metastasis</keyword>
  <keyword>Neoplasm metastasis</keyword>
  <keyword>Cranial irradiation</keyword>
  <keyword>Radiosurgery</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Kidney Neoplasms</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Carcinoma, non-small cell lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

